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Abstract: We report the case of a 30-year-old Japanese woman with anorexia nervosa and 
vertebral fractures who was treated with etidronate. She had a history of anorexia nervosa, 
chronic back pain, osteoporosis, and multiple vertebral fractures (morphometric fractures) that 
responded poorly to treatment with alfacalcidol (1 µg daily) for 1 year and was treated with 
cyclical etidronate (200 mg for 2 weeks every 3 months) for 7 years. The lumbar spine bone 
mineral density (BMD) increased, and the serum alkaline phosphatase and urinary cross-linked 
N-terminal telopeptides of type I collagen levels and back pain decreased. During the 7-year 
period of treatment with etidronate, no osteoporotic fractures occurred. The patient experienced 
neither renal dysfunction nor hyperparathyroidism caused by osteomalacia. No gastrointestinal 
tract symptoms were observed. Thus, etidronate was effective for increasing the lumbar spine 
BMD and reducing back pain over a 7-year period without causing either osteoporotic fractures 
or adverse events.
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Background
Anorexia nervosa is an eating disorder characterized by refusal to maintain a healthy 
body weight and an obsessive fear of gaining weight. A Japanese epidemiological 
survey on anorexia nervosa in 1985 and 1992 revealed that the prevalence was 3.6–4.5 
per 100,000 among the general population, 6.3–9.7 per 100,000 among the female 
population, and 25.2–30.7 per 100,000 among the 13–29 year-old female population.1 
Another Japanese epidemiological survey on anorexia nervosa in a geographically 
defined area (Niigata Prefecture) in 1997 also showed that the estimated prevalence was 
4.8 per 100,000 females and 17.1 for the age group of 15–29 years.2 The prevalence 
of anorexia nervosa in the Japanese population may be decreasing and appears to be 
lower than in European Caucasian populations.
Osteoporosis is a very prevalent complication of anorexia nervosa. It places patients 
at an increased lifetime risk for fractures. The loss of bone mineral density (BMD) can 
occur rapidly and very early during the course of anorexia nervosa.3 Early detection 
and weight restoration are of utmost importance.4 Although an improvement in BMD 
is possible after a substantial body mass increase in conjunction with a well-balanced, 
controlled diet, BMD loss may never recover completely, even once weight has been 
restored.3
The etiology of osteoporosis in patients with anorexia nervosa is multifactorial. 
In addition to reduced estrogen and progesterone levels, excess cortisol levels and Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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low   levels of insulin growth factor-1 (IGF-1) and leptin, 
a   correlate for bone formation, are observed.3–6 Bone 
resorption is also considered to be of great importance for 
osteoporosis.7 Successful treatments to reverse BMD loss 
in patients with anorexia nervosa are lacking,3 and no good 
evidence to guide medicinal interventions is available.4 
Antiresorptive agents such as bisphosphonates are one 
candidate for the treatment of osteoporosis in patients with 
anorexia nervosa.
Etidronate is a bisphosphonate that inhibits osteoclast-
mediated bone resorption.8 It has been used in the treatment 
of postmenopausal osteoporosis. A study in Japan showed 
that the percentage increase in the lumbar spine BMD after 
1 year of etidronate treatment (200 mg daily for 2 weeks 
every 3 months) was 2.4% in patients with involutional 
  osteoporosis.9 Systematic reviews have revealed that the 
relative risk (95% confidence interval) for developing ver-
tebral fractures during treatment with etidronate (400 mg 
for 2 weeks every 12 weeks) as a secondary prevention is 
0.53 (0.32 to 0.87) in Western patients with postmenopausal 
  osteoporosis.10 Thus, etidronate may be effective for increas-
ing the lumbar spine BMD and preventing vertebral frac-
tures in patients with high bone turnover and   osteoporosis. 
  However, very few reports have shown the long-term outcome 
of bisphosphonate treatment in young patients with anorexia 
nervosa and osteoporosis. We report the case of a young 
woman who had a history of anorexia nervosa, chronic back 
pain, osteoporosis, and multiple vertebral fractures (morpho-
metric fractures) who was treated with cyclical etidronate for 
7 years, showing changes in the lumbar spine BMD, bone 
turnover marker levels, and back pain.
Case report
Characteristics of the case
A premenopausal Japanese woman, 30 years of age, con-
sulted our clinic because of spinal deformity (round back) and 
chronic back pain. Despite these subjective symptoms, which 
had continued for several years, she had never been examined 
or treated for them. She had a history of anorexia nervosa 
treated for 5 years in a psychiatry clinic before her first con-
sultation with our clinic. She had lost 10 kg as a result of 
anorexia but had gained 20 kg as a result of bulimia nervosa 
after her psychiatric treatment. At the time of her consulta-
tion with our clinic, her height was 145 cm, her body weight 
was 59 kg, and her body mass index (BMI) was 28.1 kg/m2. 
  Treatment of anorexia nervosa appeared to be successful, 
and she had already recovered from the eating disorder. She 
did not have any disturbance in menstruation at the time of 
her consultation with our clinic. According to the Japanese 
criteria,11 she was considered obese (BMI . 25 kg/m2). 
She had no past history of reflux esophagitis, gastric or duo-
denal ulcer, gastrectomy, or metabolic bone diseases and had 
never taken medicine that affected bone metabolism.
The level of chronic back pain was 5, as evaluated quanti-
tatively by assessing the mood of the patient according to the 
face scale score (scores are arranged in decreasing order of 
mood and numbered from 1–10, with 1 representing the most 
positive mood and 10 representing the most negative mood).12 
She had stiffness and tenderness in her back muscles. How-
ever, she did not have any neurological deficits.
The radiographs of the thoracic and lumbar spine showed 
multiple vertebral fractures (morphometric fractures) in 
the thoracic and lumbar spine according to the Japanese 
diagnostic criteria for osteoporotic vertebral fractures13,14 
and increased kyphosis of the thoracic spine (Figure 1). To 
understand the pathogenesis of bone fragility and to deter-
mine an effective treatment using medication, the lumbar 
spine BMD was measured and biochemical analyses were 
performed. Table 1 shows the baseline BMD and biochemical 
markers. The lumbar spine (L1–L4) BMD was 0.803 g/cm2, 
corresponding to 77% of the young adult mean (YAM). The 
patient was diagnosed as having osteoporosis according to 
the Japanese criteria in women:13,14 patients whose BMD 
was ,70% of the YAM or 70%–80% of the YAM and who 
had a history of osteoporotic fractures are regarded as having 
osteoporosis. The serum calcium, phosphorus, alkaline phos-
phatase (ALP), and creatinine levels measured using standard 
laboratory techniques were within the normal ranges. The 
serum intact parathyroid hormone (PTH) level measured using 
a chemiluminescent immunoassay (CLIA) was within the 
normal range. The patient had no other abnormalities in their 
blood examinations. The active form of vitamin D3, vitamin 
K2, intramuscular elcatonin, and etidronate were available for 
the treatment of osteoporosis. Bone turnover markers, such as 
bone-specific ALP and cross-linked N-terminal telopeptides 
of type I collagen (NTX), were also not available.
Outcome of 1 year of alfacalcidol 
treatment
Alfacalcidol treatment (1 µg daily) was started despite the 
lack of secondary hyperparathyroidism because this was 
the standard treatment for osteoporosis at that time. The 
lumbar spine BMD, serum calcium, phosphorus, ALP   levels, 
and the face scale score (for back pain) were evaluated 
every 6 months. Radiographs of the thoracic and lumbar 
spine were also taken every year to identify new vertebral Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Thoracic spine Lumbar spine
L1
L1
Figure 1 Radiographs of the thoracic and lumbar spine – lateral views before 
treatment. The radiographs of the thoracic and lumbar spine at her first consultation 
with our clinic showed multiple vertebral fractures (morphometric fractures) in the 
thoracic and lumbar spine and increased kyphosis of the thoracic spine.
Table 1 Baseline BMD and biochemical markers
Normal range
Lumbar spine BMD (g/cm2) 0.803
% YAM in BMD 77
serum
  Calcium (mg/dL) 9.5 8.4–10.2
  Phosphorus (mg/dL) 3.4 2.5–4.5
  ALP (IU/L) 320 100–340
  Intact PTH (pg/mL) 17 10–66
  Total protein (g/dL) 7.7 6.5–8.2
  Albumin (g/dL) 4.3 3.7–5.2
  Asparate aminotransferase (U/L) 19 11–35
  Creatinine (mg/dL) 0.52 0.47–0.79
  Total cholesterol (mg/dL) 206 130–219
  HDL-cholesterol (mg/dL) 48.2 40–90
  LDL-cholesterol (mg/dL) 135 70–139
  Triglyceride (mg/dL) 114 30–149
  WBC (1/µL) 5400 3500–9100
  RBC (×104/µL) 459 376–516
  Hemoglobin (g/dL) 13.2 11.2–15.2
  Platelet (×104/µL) 21.1 14.0–37.9
Abbreviations: BMD, bone mineral density; YAM, young adult mean; ALP, alkaline 
phosphatase; PTH, parathyroid hormone; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; WBC, white blood cell; RBC, red blood cell.
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Figure 2 Changes in lumbar spine BMD. After 1 year of alfacalcidol treatment, the 
lumbar spine BMD decreased. Then, treatment was switched to cyclical etidronate 
and was sustained for 7 years. The lumbar spine BMD increased after the start of 
etidronate treatment. The increase rate was 3.6% at 1 year, 8.4% at 2 years, 8.4% at 
3 years, 6.8% at 4 years, 6.7% at 5 years, 8.3% at 6 years, and 8.1% at 7 years.
Abbreviations: ALF, alfacalcidol; BMD, bone mineral density; eTD, etidronate.
fractures. After 1 year of alfacalcidol treatment, however, 
the lumbar spine BMD decreased (Figure 2) and the face 
scale score (back pain) did not improve, although no new 
vertebral fractures occurred. The serum ALP level did not 
change significantly during the 1-year period of alfacalcidol 
treatment (Figure 3). The serum calcium, phosphorus, and 
creatinine levels were within the normal ranges. Therefore, 
alternative treatments needed to be considered because the 
young female patient was anxious about the progression of 
kyphosis of the thoracic spine.
Outcome of 7 years of etidronate 
treatment
The patient was evaluated again by measuring the lumbar 
spine BMD and the serum calcium, phosphorus, ALP, intact 
PTH, and urinary NTX levels (Table 2). Measurement of the 
urinary NTX level, a bone turnover marker, recently became 
available. The urinary NTX level measured using an enzyme-
linked immunosorbent assay (ELISA) was 88.4 nM BCE/
mM Cr, suggesting high bone turnover osteoporosis (normal 
range: 35.3–54.3 nM BCE/mM Cr).15 The serum calcium, 
phosphorus, and ALP levels were within the normal ranges. 
The serum intact PTH level was also within the normal 
range, suggesting the absence of hyperparathyroidism. The 
face scale score (back pain) was 5. After informed consent 
was obtained from the patient, treatment was switched to 
the antiresorptive agent cyclical etidronate (200 mg daily 
for 2 weeks every 3 months) and was sustained for 7 years. 
Nitrogen-containing bisphosphonates like alendronate and 
risedronate or anabolic agents like teriparatide were not 
available at the time when etidronate treatment was started. 
The urinary NTX level was measured after 3 months of 
etidronate treatment. The lumbar spine BMD, serum calcium, 
phosphorus, ALP, creatinine levels, and the face scale score 
(for back pain) were evaluated every 6 months during the 
7-year period of etidronate treatment. Radiographs of the 
thoracic and lumbar spine were also taken every year to 
identify new vertebral fractures. In Japan, the measurement 
of the urinary NTX level is covered by health insurance only 
twice (at the start of medication and within 6 months after 
the start of medication). Because the measurement of the Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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serum bone-specific ALP (bone formation marker) level is 
not covered by health insurance for the monitoring of osteo-
porosis treatment, we substituted the serum total ALP level 
as a bone formation marker.
Figure 2 shows the longitudinal changes in the lumbar 
spine BMD during the 7-year period of etidronate treat-
ment. The lumbar spine BMD increased after the start of 
etidronate treatment. The increase rate was 3.6% at 1 year, 
8.4% at 2 years, 8.4% at 3 years, 6.8% at 4 years, 6.7% 
at 5 years, 8.3% at 6 years, and 8.1% at 7 years. The uri-
nary NTX level decreased to 45.2 nM BCE/mM Cr after 
3 months of etidronate treatment. The reduction rate was 
48.9%.   Figure 3 shows the longitudinal changes in the 
serum calcium, phosphorus, ALP, and creatinine levels 
during the 7-year period of etidronate treatment. The serum 
ALP markedly decreased. The rate of reduction in the 
serum ALP level was 40.0% at 1 year, 51.5% at 2 years, 
and 48.8% at 3 years. This reduction was sustained after 
3 years (46.4% at 4 years, 46.7% at 5 years, 46.7% at 
5 years, and 46.1% at 7 years). The serum calcium, phos-
phorus, and creatinine levels stayed within the normal 
ranges during the 7-year period of etidronate treatment. 
After 7 years of etidronate treatment, the serum PTH 
level was 13 pg/mL, which was within the normal range. 
The face scale score (for back pain) decreased to 3 after 
6 months of etidronate treatment. At that time, the patient 
began walking for exercise (30 minutes of outdoor walking) 
3–4 days a week for the treatment of obesity. This reduc-
tion in back pain was maintained after 6 months (face scale 
score was 2 or 3 thereafter). Her body weight decreased 
to 50 kg (BMI: 23.8 kg/m2) after 1 year of   exercise. After 
7 years of treatment, her height was 144 cm, her body 
weight was 46 kg, and her BMI was 22.2 kg/m2, indicating 
the absence of obesity.
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Figure 3 Changes in serum calcium, phosphorus, ALP, and creatinine. After 1 year of treatment with alfacalcidol, the serum ALP level did not change significantly. Then, 
treatment was switched to cyclical etidronate and was sustained for 7 years. The serum ALP markedly decreased. The rate of reduction in the serum ALP level was 40.0% 
at 1 year, 51.5% at 2 years, and 48.8% at 3 years. This reduction was sustained after 3 years (46.4% at 4 year, 46.7% at 5 years, 46.7% at 5 years, and 46.1% at 7 years). The 
serum calcium, phosphorus, and creatinine levels stayed within the normal ranges during the 7-year period of etidronate treatment.
Abbreviations: ALF, alfacalcidol; ALP, alkaline phosphatase; eTD, etidronate.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 BMD and biochemical markers after 1-year alfacalcidol 
treatment
Normal range
Lumbar spine BMD (g/cm2) 0.775
% YAM in BMD 74
serum
  Calcium (mg/dL) 9.5 8.4–10.2
  Phosphorus (mg/dL) 2.8 2.5–4.5
  ALP (IU/L) 330 100–340
  Intact PTH (pg/mL) 15 10–66
Urine
  NTX (nM BCe/mM Cr) 88.4 9.3–54.3
Abbreviations: BMD, bone mineral density; YAM, young adult mean; ALP, alkaline 
phosphatase; NTX, cross linked N-terminal telopeptides of type I collagen; BCe, 
bone collagen equivalent; Cr, creatinine.
Thoracic spine Lumbar spine
L1
L1
Figure  4  Radiographs  of  the  thoracic  and  lumbar  spine  –  lateral  views  after 
treatment.  The  radiographs  of  the  thoracic  and  lumbar  spine  after  1  year  of 
treatment with alfacalcidol and 7-year treatment with etidronate showed no new 
incident vertebral fractures.
After 7 years of etidronate treatment, radiographs of 
the thoracic and lumbar spine revealed no evidence of new 
thoracic or lumbar vertebral fractures (Figure 4). During 
the 7-year period of etidronate treatment, nonvertebral 
osteoporotic fractures did not occur in the hip, wrist, or 
shoulder.
No adverse gastrointestinal symptoms were observed. 
As shown by the serum creatinine and intact PTH levels, the 
patient experienced neither renal dysfunction nor secondary 
hyperparathyroidism as a result of osteomalacia.
Discussion
We report the case of a young woman who had a history 
of anorexia nervosa, chronic back pain, osteoporosis, and 
multiple vertebral fractures (morphometric fractures) treated 
with cyclical etidronate for 7 years. BMD loss in patients 
with anorexia nervosa is thought to never recover completely, 
even once the body weight has been restored.1 Although body 
weight was gained as a result of bulimia after psychiatric 
treatment, the current patient had osteoporosis and multiple 
vertebral fractures. However, successful treatments to reverse 
BMD loss in patients with anorexia nervosa are lacking.1 
The discussion points are 1) whether etidronate treatment is 
suitable for young women with multiple vertebral fractures, 
2) the long-term efficacy and safety of etidronate treatment, 
3) the mechanism for the pain relief effect of etidronate 
treatment, and 4) how long etidronate treatment should be 
continued.
The contraindications for etidronate treatment are severe 
renal dysfunction, osteomalacia, pregnancy, and childhood. 
The current patient had neither renal dysfunction nor second-
ary hyperparathyroidism caused by osteomalacia. The patient 
was a young woman (30 years old) but was not pregnant. The 
safety of bisphosphonate treatment during human pregnancy 
has not been well established. However, Ornoy et al16 reported 
that no major congenital abnormalities were found in the 
offspring of 24 women who were treated with alendronate 
before or at the beginning of pregnancy. Levy et al17 suggest 
that preconceptional and first-trimester use of bisphospho-
nates may not pose substantial fetal risks. Vujasinovic-Stupar 
et al18 reported that sequential treatment with etidronate and 
pamidronate increased the lumbar spine BMD and reduced 
back pain in a young woman with pregnancy-associated 
spinal osteoporosis but did not cause any neonatal adverse 
effects. They implied that although the prepregnancy use of 
bisphosphonates does not pose a substantial fetal risk, their 
use in women of childbearing age may best be done only when 
strong clinical indications exist. Etidronate will be liberated by 
the skeleton only when the bone in which the drug is deposited 
is destroyed; its half-life in the body is dependent on the rate of 
bone turnover and may be in excess of 1 year.19 Etidronate was 
considered to be acceptable in young patients with multiple 
fractures in terms of the treatment of severe osteoporosis, who 
did not have the possibility of a future pregnancy in several 
years. The current patient was able to understand the possible 
influence of etidronate on the fetal skeleton.
Alfacalcidol was often used for the treatment of osteopo-
rosis before etidronate became available. A study showed that 
alfacalcidol treatment (1 µg daily) and calcium supplementa-
tion sustained the lumbar spine BMD (0.65% increase from 
the baseline) in Japanese postmenopausal women with osteo-
porosis.20 However, because the current patient was thought 
to have responded poorly to 1 year of alfacalcidol treatment, 
her medication was switched to etidronate. We were not able 
to evaluate serum 25-hydroxyvitamin D. However, based on Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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the low serum PTH level, the patient was suggested not to 
have hypovitaminosis D or secondary   hyperparathyroidism. 
A few reports have shown the long-term efficacy of etidronate 
treatment in patients with osteoporosis. Sato et al21 reported 
that long-term (7 years) cyclical etidronate treatment 
(200 mg/day for 2 weeks every 3 months) and alfacalcidol 
(0.75 µg daily) plus calcium supplementation were safe and 
effective for the prevention and treatment of glucocorticoid-
induced osteoporosis in Japanese patients with connective 
tissue diseases (age: 21–73 years). The increase in the lumbar 
spine BMD at the end of 7 years was 6.7% in the subgroup 
of premenopausal women.21 Miller et al22 also reported the 
efficacy and safety of long-term (7 years) cyclical etidronate 
treatment (400 mg/day for 2 weeks every 12 weeks) and 
calcium supplementation in postmenopausal Western women 
with osteoporosis. The increase in the lumbar spine BMD at 
the end of 7 years was 7.6%, and the incidence of vertebral 
fractures was reduced after 7 years of etidronate treatment.22 
These reports suggest that long-term cyclical etidronate is 
a safe and effective treatment for osteoporosis. The current 
case report confirmed the long-term efficacy and safety of 
etidronate treatment, and the increase in the lumbar spine 
BMD after 7 years of etidronate treatment was 8.1%, con-
sistent with the results of previous studies.21,22
After her back pain decreased following 6 months of 
etidronate treatment, the patient began walking for exercise 
(30 minutes of outdoor walking) 3–4 days a week for the 
treatment of obesity. Available evidence suggests that aero-
bics, weight-bearing, and resistance exercises are all effective 
in increasing the BMD of the lumbar spine and that walking 
is effective on the hips in postmenopausal women.23 How-
ever, although high-intensity progressive resistance training 
is efficacious in increasing the BMD of the lumbar spine 
in premenopausal women, the effect of walking exercise 
on the BMD remains to be established in young women.23 
  Consequently, it remains uncertain whether there was an 
additive effect of etidronate and walking exercise on the 
lumbar spine BMD in the current patient.
Etidronate decreased back pain. However, the mechanism 
responsible for the pain relief effect of bisphosphonates 
remains uncertain. One possible mechanism may involve 
bone resorption, because the efficacy of bisphosphonates 
for bone pain in patients with avascular necrosis of the 
hip, osteoporotic vertebral fractures, skeletal metastases, 
or Paget’s disease of the bone has been demonstrated.24–28 
Other possibilities may involve neuropeptides that are 
active during pain transmission, such as substance P and 
calcitonin   gene-related peptide (CGRP), and inflammatory 
cytokines, such as tumor necrosis factor-α (TNF-α).29–32 
Bisphosphonates may suppress the production of substance 
P, CGRP, and TNF-α,33,34 possibly reducing back pain.
How long patients with osteoporosis can continue to 
receive bisphosphonate treatment remains to be established. 
The prolonged suppression of remodeling is associated with 
the accumulation of microdamage, advanced glycation 
products, and an increased tissue mineral density, while stop-
ping treatment results in the reemergence of remodeling.35 
Seeman inferred that stopping antiresorptive treatment was 
more likely to do net harm than continuing the treatment.35 
Thus, antiresorptive treatment should be continued as long 
as possible in patients at risk of fractures. The current patient 
continued etidronate treatment for 7 years. Neither osteoporo-
tic fractures nor adverse events occurred during this time. 
The patient is continuing etidronate treatment and is being 
carefully followed-up by physicians.
The clinical risk factors of fractures in Japan include 
current smoking, maternal history of hip fractures, alcohol 
consumption (.2 units daily), age (.75 years), leanness 
(body mass index ,18.5 kg/m2), and history of steroid use.36 
Thus, weight loss due to anorexia nervosa can partly contrib-
ute to occurrence of osteoporosis. Vertebral fractures related 
to osteoporosis are more common in Japanese elderly than in 
Caucasian elderly.37 The incidence of vertebral fractures in the 
50s, 60s, 70 s, and 80s is reported to be 5.2, 12.4, 24.5, and 
56.1 per 1000 person-years, respectively in Japanese women 
without a vertebral fracture and 36.2, 59.7, 88.0, and 141.0 
per 1000 person-years, respectively in Japanese women with 
a prior vertebral fracture.37 Thus, the incidence of vertebral 
fracture increases approximately exponentially with age after 
50 years.37 Although vertebral fractures are not common in 
Japanese women ,50 years of age, osteoporosis is a very 
prevalent complication in young women with anorexia ner-
vosa. Thus, the strategy for preventing osteoporotic fractures 
in young women with a history of anorexia nervosa needs to 
be established. This case report may be intriguing, especially 
because it raises additional questions that could stimulate 
further research.
In conclusion, we report the case of a young woman with 
a history of anorexia, chronic back pain, osteoporosis, and 
multiple vertebral fractures (morphometric fractures) who 
was treated with cyclical etidronate for 7 years. Etidronate 
was effective in increasing the lumbar spine BMD and reduc-
ing back pain without causing either osteoporotic fractures 
or adverse events. However, further careful observation is 
needed to confirm the safety of etidronate in young women 
with osteoporosis and possibly fetuses.Therapeutics and Clinical Risk Management
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